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ABSTRACT
In this study, we used mice lacking the G11a [G11 knockout (KO)]
or Gqa gene (Gq KO) to examine LH release in response to a meta-
bolically stable GnRH agonist (Buserelin). Mice homozygous for the
absence of G11a and Gqa appear to breed normally. Treatment of (5
wk old) female KO mice with the GnRH agonist Buserelin (2 mg/100
ml, sc) resulted in a rapid increase of serum LH levels (reaching 328 6
58 pg/25 ml for G11 KO; 739 6 95 pg/25 ml for Gq KO) at 75 min. Similar
treatment of the control strain, 129SvEvTacfBr for G11 KO or the
heterozygous mice for Gq KO, resulted in an increase in serum LH
levels (428 6 57 pg/25 ml for G11 KO; 884 6 31 pg/25 ml for Gq KO)
at 75 min. Both G11 KO and Gq KO male mice released LH in response
to Buserelin (2 mg/100 ml of vehicle; 363 6 53 pg/25 ml and 749 6 50
pg/25 ml 1 h after treatment, respectively). These values were not
significantly different from the control strain. In a long-term exper-
iment, Buserelin was administered every 12 h, and LH release was
assayed 1 h later. In female G11 KO mice and control strain, serum
LH levels reached approximately 500 pg/25 ml within the first hour,
then subsided to a steady level (;100 pg/25 ml) for 109 h. In male G11
KO mice and in control strain, elevated LH release lasted for 13 h;
however, LH levels in the G11 KO male mice did not reach control
levels for approximately 49 h. In a similar experimental protocol, the
Gq KO male mice released less LH (531 6 95 pg/25 ml) after 13 h from
the start of treatment than the heterozygous male mice (865 6 57
pg/25 ml), but the female KO mice released more LH (634 6 56 pg/25
ml) after 1 h from the start of treatment than the heterozygous female
mice (346 6 63 pg/25 ml). However, after the initial LH flare, the LH
levels in the heterozygous mice never reached the basal levels
achieved by the KO mice. G11 KO mice were less sensitive to low doses
(5 ng/per animal) of Buserelin than the respective control mice. Male
G11 KO mice produced more testosterone than the control mice after
1 h of stimulation by 2 mg of Buserelin, whereas there was no sig-
nificant difference in Buserelin stimulated testosterone levels be-
tween Gq KO and heterozygous control mice. There was no significant
difference in Buserelin stimulated estradiol production in the female
Gq KO mice compared with control groups of mice. However, female
G11 KO mice produced less estradiol in response to Buserelin (2 mg)
compared with control strain. Although there were differences in the
dynamics of LH release and steroid production in response to Buse-
relin treatment compared with control groups of mice, the lack of
complete abolition of these processes, such as stimulated LH release,
and steroid production, suggests that these G proteins are either not
absolutely required or are able to functionally compensate for each
other. (Endocrinology 139: 2710–2717, 1998)
GnRH STIMULATES LH and FSH release from the an-terior pituitary. Several pieces of evidence implicated
G protein involvement in GnRH receptor mediated actions.
First, GTP and its analogs stimulate LH release and inositol
phosphate production in permeabilized pituitary cell cul-
tures (1) and provoke the characteristic decrease in affinity
of the GnRH receptor for its ligand (2). Second, the GnRH
receptor has seven transmembrane segments characteristic
of G protein-coupled receptors (3).
Multiple G proteins appear to be involved in mediating the
response of the gonadotrope to GnRH (4, 5). GnRH is capable
of stimulating IP release through pertussis toxin-sensitive G
proteins, whereas a cholera toxin-sensitive G protein appears
to provoke gonadotrope sensitization to GnRH and other
secretagogues. Immunodepletion studies from aT3–1 cell
membranes suggest that the GnRH receptor is coupled to
Gq/11a protein (6), and more recently we have shown that the
GnRH receptor regulates Gq/11a in rat pituitary cell cultures
and in GGH3 cells that stably express the GnRH receptor (7).
Stimulation with GnRH also provokes palmitoylation and
redistribution of Gq/11a in primary pituitary cultures (7, 8).
The Gqa subfamily includes Gqa, G11a, G14a, G15a, and
G16a (9). These G proteins are capable of activating phos-
pholipase C-b (PLCb) and are unmodified by pertussis toxin
(10, 11). Gqa and G11a have 88% amino acid sequence iden-
tity (10). In SDS-PAGE, Gqa and G11a migrate at 41–42 kDa
(12). Due to the structural similarities between Gqa and G11a,
it is technically difficult to discriminate between the two G
proteins by biochemical approaches.
Very few studies are available to attribute a specific ac-
tivity to either Gqa or G11a, and the likelihood exists that
these two proteins functionally compensate for each other.
Studies done on Swiss 3T3 cells, for example, indicate that
bombesin and vasopressin receptors concurrently activate
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both Gqa and G11a (13), suggesting that, with respect to
phospholipase C-b activation, these two proteins may func-
tion interchangeably. However, when a1A/D, a1B and a1C
adrenergic receptors are activated by agonists, Gqa and G11a
proteins, which are activated by these receptors, are de-
graded at a similar rate, an observation suggesting that the
G proteins may couple to these receptors without any pref-
erence (14). Furthermore, in Xenopus oocytes, Gqa and G11a
show similar modulation of response to TSH releasing hor-
mone (15), suggesting that these two proteins activate similar
effectors, although an earlier report in the same system sug-
gests that the response to TSH-releasing hormone is differ-
entially coupled to downstream effectors by Gqa and G11a
proteins (16).
All of these studies were performed either in transfected
cell lines or in Xenopus oocytes. Therefore, little is known
about the G protein coupling to the GnRH receptor in intact
animals, particularly under endocrine systems with complex
feedback mechanisms. To examine this question with respect
to G protein-coupling to the GnRH receptor, we examined
the role of Gqa and G11a in the mouse gonadotrope by using
knockout mice, lacking either the Gqa or the G11a protein.
This study provides evidence to suggest that Gqa and G11a
proteins can functionally compensate for each other in GnRH
analog stimulated LH release and steroidogenesis.
Materials and Methods
Preparation of mice lacking the G11a gene
G11a knockout mice were prepared from 129/SvEv strain of mice as
previously described (Wilkie, T., manuscript submitted). For control
experiments 129/SvEvTacfBR strain of mice (Taconic Farms, German-
town, NY) were used. Both control mice and knockout mice were 5
weeks old, and weighed approximately 16–18 g. The breeding pair of
G11a knockout mice were homozygous for the knockout gene. The
weight to age curves, litter size, and other external characteristics were
indistinguishable between 129/SvEvTacfBR mice and knockout mice.
Therefore, we used age-matched 129/SvEvTacfBR strain as controls.
Preparation of mice lacking the Gqa gene
Gqa knockout mice were prepared as previously described (18). Male
mice homozygous for the Gqa knockout were mated to female mice
heterozygous for the Gqa knockout. Offspring that were heterozygous
for the Gqa knockout were used as control mice. The experiments were
performed at 5 weeks of age, and at this time, both homozygous
and heterozygous mice for the knockout gene weighed approximately
15–18 g each. The mice were genotyped at 3 weeks to identify the
homozygous knockout mice in the litter. To keep the variations between
the animals to a minimum, heterozygous mice from the same litter was
used as controls. Heterozygous mice, who have only one functioning
Gqa gene, do not show any adverse effects. These mice have weight to
age curves similar to the wild-type mice and were indistinguishable
from the wild-type mice. Thus, heterozygous mice from the same litter
were an appropriate control.
Genotyping of Gqa knockout mice
Approximately 0.5 cm size section of the mouse tails were digested
overnight under constant agitation at 50 C in 300 ml of digestion buffer
(100 mm EDTA, 0.5% SDS, 0.5 mg/ml proteinase K and 50 mm Tris-HCl;
pH 8). The digested samples were spun at 12,000 3 g for 2 min, and 200 ml
of the supernatant was mixed with 100 ml of 7.5 m ammonium acetate
to obtain a final concentration of 2.5 m. Genomic DNA was precipitated
by adding 600 ml of ice cold ethanol and collected at 12,000 3 g for 10
min. The DNA pellet was washed once with 70% ethanol and dried.
Finally, the DNA pellet was dissolved in 300 ml of Tris-EDTA buffer
(pH 8).
A 150-bp sequence of the disrupted Gqa gene containing the neo-
mycin gene was amplified by PCR with flanking primers NEO4 (59
GATTCGCAGCGCATCGCCTTCTAT 39) and QNEO (59 TTCAAAG-
TATCACACTCACATCACAG 39). A 150-bp sequence of the wild-type
Gqa gene was amplified with the flanking primers 5EXQ (59 GAAC-
CGCATGGAGGAGAGCAAAGC 39) and 3EXQ (59 CTGGGAAGTAG
TCGACTAGGTGGG 39). The PCR protocol used is as follows: 5 min at
94 C, 35 cycles of 1 min at 94 C, 1 min at 63 C and 3 min at 72 C, and
finally 10 min at 72 C.
Serum collection and LH RIA
Each mouse received 2 mg of Buserelin (GnRH agonist, Hoechst) in
100 ml of vehicle (PBS/0.3% BSA) or vehicle alone. This is a saturating
dose of Buserelin with respect to LH release (19). For the dose-response
studies, indicated doses of Buserelin in 100 ml of vehicle was given.
Buserelin was injected sc into the skin behind the neck. Mice were
anesthetized with methoxyflurane, and serum collected at the indicated
times by intraorbital puncture. In long time course experiments, serum
was collected 1 h after injection of Buserelin. Serum was aliquoted and
stored at 220 C before assay.
The RIA used a highly purified rat LH for iodination (NIDDK; 20) and
a mouse reference preparation obtained as a kind gift from Dr. Al Parlow
(Harbor-UCLA Hospital, Torrance, CA). LH antisera (C102) was pre-
pared and characterized as previously described (21). Bound and free
proteins were separated using the second antibody technique (22). The
minimum detectable dose for the RIA was 6 6 1 pg (n 5 6) and the inter
and intraassay variance was less than 10%. The rat and mouse LH
standards were approximately identical; the rat ED20 never varied more
than 9% from the mouse ED20.
Steroid assays for testosterone and estradiol
Serum estradiol (23, 24) and testosterone (25) levels were measured
by RIA in the ORPRC RIA Laboratory using previously described meth-
ods. Antisera for estradiol (23, 24) and testosterone (25) were obtained
as previously described. For the estradiol assay, the minimum detectable
dose was approximately 0.5 pg. The intra and interassay variance was
approximately 7 and 13%, respectively. For the testosterone assay, the
minimum detectable dose was 5 pg. The intra and interassay variance
was approximately 5 and 8%, respectively.
Statistical analyses
The results are presented as the mean 6 sem of the indicated number
of animals. Data were analyzed by one-way ANOVA, followed by
Student’s t test with Bonferoni correction for multiple comparisons. To
examine the overall LH release in mice over time, a two-way ANOVA
for repeated measures was performed.
Results
Figure 1, A and B, shows, respectively, serum LH levels in
male and female G11a knockout mice, after an sc injection of
2 mg of Buserelin or vehicle. Samples were collected at 0, 15,
30, 45, and 75 min after the injection of drug or the vehicle.
In male G11a knockout mice, serum LH levels increased from
7 6 2 pg/25 ml (n 5 6) to 363 6 53 pg/25 ml (n 5 6), when
administered with 2 mg of Buserelin (Fig. 1A). In the control
strain, the same treatment of Buserelin resulted in an increase
of serum LH from 10 6 1 pg/25 ml (n 5 5) to 458 6 59 pg/
25 ml (n 5 5). When treated with the vehicle (PBS/0.1% BSA),
the serum LH levels in male G11a knockout mice and in the
male control strain remained between 7–10 pg/25 ml. In
female G11a knockout mice, serum LH levels increased from
6 6 1 pg/25 ml (n 5 7) to 328 6 58 pg/25 ml (n 5 7), when
administered with 2 mg of Buserelin (Fig. 1B). In the control
strain, the same treatment of Buserelin resulted in an increase
Gqa AND G11a KNOCKOUTS 2711
of serum LH from 10 6 1 pg/25 ml (n 5 6) to 428 6 57 pg/25
ml (n 5 6). LH released in response to Buserelin was not
significantly different (P , 0.05) in both male and female
G11a knockout mice compared with control mice. When
treated with the vehicle (PBS/0.1% BSA), the serum LH
levels in female G11a knockout mice and in female control
strain remained between 6–10 pg/25 ml.
Figure 2, A and B, shows serum LH levels in mice 1 h after
an sc injection of 2 mg of Buserelin given every 12 h for 108 h.
In male G11a knockout mice, the serum LH levels reached a
maximum of 753 6 29 pg/25 ml (n 5 7) after 13 h from the
start of treatment (Fig. 2A). In the male control strain, a
similar treatment resulted in a maximum LH level of 507 6
27 pg/25 ml (n 5 6) after 13 h from the start of treatment. After
61 h from the start of treatment, the serum LH levels in the
male G11a knockout mice reached the serum LH level of the
control mice. Male G11a knockout mice released significantly
(P , 0.05) more LH over time than male control mice. In
female G11a knockout mice, the serum LH levels reached a
maximum of 579 6 88 pg/25 ml (n 5 5) after 1 h from the
start of treatment (Fig. 2B). In the female control strain, a
similar treatment resulted in a maximum LH level of 461 6
45 pg/25 ml (n 5 7) after 1 h from the start of treatment. The
serum LH levels in female G11a knockout mice and control
strain were maintained at similar levels after 13 h from start
of treatment. There was no significant (P , 0.05) differences
in LH release over time between the female G11a knockout
mice and female control mice.
Figure 3, A and B, shows, respectively, the serum LH level
in male and female Gqa knockout mice after an sc injection
of 2 mg of Buserelin or vehicle. Samples were collected at 0,
15, 30, 45, and 75 min after the injection of drug or the vehicle.
In male Gqa knockout mice, serum LH levels increased from
8 6 0 pg/25 ml to 749 6 50 pg/25 ml (n 5 5), when admin-
istered with 2 mg of Buserelin (Fig. 3A). In the heterozygous
strain, the same treatment of Buserelin resulted in an increase
of serum LH from 10 6 2 pg/25 ml to 765 6 85 pg/25 ml (n 5
5). When treated with vehicle (PBS/0.1% BSA), the serum LH
levels in male Gqa knockout mice and in male control strain
remained between 9–10 pg/25 ml (data not shown). In female
Gqa knockout mice, serum LH levels increased from 7 6
0 pg/25 ml to 740 6 95 pg/25 ml (n 5 9), when administered
with 2 mg of Buserelin (Fig. 3B). In the female heterozygous
strain, the same treatment of Buserelin resulted in an increase
of serum LH from 9 6 1 pg/25 ml to 884 6 31 pg/25 ml (n 5
6). LH released in response to Buserelin was not significantly
different (P , 0.05) in both male and female Gqa knockout
FIG. 1. A and B show, respectively, serum LH levels in male and
female G11a knockout mice, after an sc injection of 2 mg of Buserelin
or vehicle. Samples were collected at the indicated times, and LH
released was assayed by RIA as mentioned in Materials and Methods.
Data represent the mean 6 SEM.
FIG. 2. A and B show serum LH levels in G11a knockout male and
female mice, respectively, 1 h after an sc injection of 2 mg of Buserelin
given every 12 h for 108 h. Samples were collected, and LH released
was assayed by RIA as mentioned in Materials and Methods. The data
represent the mean 6 SEM. Data points with asterisks are significantly
different (P , 0.05) from the corresponding data points for the control
strain.
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mice compared with heterozygous mice. When treated with
the vehicle (PBS/0.1% BSA), the serum LH levels in female
Gqa knockout mice and in female heterozygous mice re-
mained between 9–10 pg/25 ml (data not shown).
Figure 4, A and B, shows serum LH levels in Gqa knockout
mice 1 h after an sc injection of 2 mg of Buserelin given every
12 h for 108 h. In male Gqa knockout mice, the serum LH level
reached a maximum of 556 6 43 pg/25 ml (n 5 7) after 1 h
from the start of treatment (Fig. 4A). In the heterozygous
male, a similar treatment resulted in LH levels of 570 6
60 pg/25 ml (n 5 4) after 1 h from the start of treatment, a
maximum serum LH level of 865 6 57 pg/25 ml was achieved
after 13 h from the start of treatment. The serum LH levels
of the heterozygous male mice never returned to the serum
LH levels of the Gqa knockout mice during the treatment
period. In female Gqa knockout mice, the serum LH level
reached a maximum of 634 6 56 pg/25 ml (n 5 4) after 1 h
from the start of treatment (Fig. 4B). In the heterozygous
strain, a similar treatment resulted in a maximum LH level
of 346 6 63 pg/25 ml (n 5 7) after 1 h from the start of
treatment. The serum LH level in female Gqa knockout mice
was maintained after the initial LH flare below the heterozy-
gous serum LH levels. There was a significant (P , 0.05)
difference in LH release over time (both males and females)
between Gqa knockout and heterozygous mice.
To examine whether the sensitivity of the gonadotrope is
different between the knockout and control mice, we inves-
tigated the amount of LH released in response to different
doses of Buserelin. Figure 5, A and B, shows the LH released
after 1 h in response to the indicated doses of Buserelin in
G11a knockout male and female mice, respectively. There is
no significant difference between the knockout mice and
control mice at doses above 0.05 mg of Buserelin. The control
mice responded more robustly to a 5 ng/per animal dose of
Buserelin than the knockout mice; 448 6 18 pg/25 ml (n 5 5)
vs. 198 6 25 pg/25 ml (n 5 6) in male knockout mice, 417 6
23 pg/25 ml (n 5 5) vs. 175 6 24 pg/25 ml (n 5 7) in female
knockout mice.
Figure 6, A and B, shows the LH released after 1 h in
response to the indicated doses of Buserelin in Gqa knockout
male and female mice, respectively. There was a significant
difference in LH release in female Gqa knockout mice when
2 mg of Buserelin was administered; 634 6 56 pg/25 ml (n 5
4) for Gqa knockout vs. 346 6 63 pg/25 ml (n 5 4) for control.
However, unlike the G11a knockout mice, there was no sig-
nificant (P , 0.05) difference between Gqa knockout mice
and heterozygous mice with respect to LH release in re-
sponse to 0.05 mg of Buserelin.
To examine whether there is a differential response to
FIG. 3. A and B show, respectively, serum LH levels in male and
female Gqa knockout mice, after an sc injection of 2 mg of Buserelin
or vehicle. Samples were collected at the indicated times, and LH
released was assayed by RIA as mentioned in Materials and Methods.
Data represent the mean 6 SEM.
FIG. 4. A and B show serum LH levels in Gqa knockout male and
female mice, respectively, 1 h after an sc injection of 2 mg of Buserelin
given every 12 h for 108 h. Samples were collected, and LH released
was assayed by RIA as mentioned in Materials and Methods. The data
represent the mean 6 SEM. Data points with asterisks are significantly
different (P , 0.05) from the corresponding data point for the het-
erozygous mice.
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GnRH with respect to steroid production between the knock-
out mice and the control strain, we examined the production
of testosterone and estradiol in mice when injected with 2 mg
of Buserelin. Figure 7, A and B, shows the testosterone and
estradiol levels in the serum, respectively, of male and female
G11a knockout mice, before and 1 h after an sc injection of
2 mg of Buserelin. In male G11a knockout mice, serum tes-
tosterone levels increased from 2 6 1 ng/ml to 23 6 4 ng/ml
(n 5 10) in response to an sc injection of 2 mg of Buserelin.
In the male control strain, a similar treatment of Buserelin
increased serum testosterone levels from 1 6 1 ng/ml to 14 6
3 ng/ml (n 5 5). In female G11a knockout mice, we were
unable to detect a change in serum estradiol levels in re-
sponse to 2 mg of Buserelin; 8 6 1 pg/ml before Buserelin
treatment, and 6 6 1 pg/ml (n 5 12) 1 h after Buserelin
treatment. In the female control strain, serum estradiol levels
increased in response to 2 mg of Buserelin from 12 6 1 pg/ml
(n 5 4) to 17 6 2 pg/ml (n 5 5).
Figure 8, A and B, shows the serum testosterone and es-
tradiol levels, respectively, of male and female mice, before
and 1 h after an sc injection of 2 mg of Buserelin in Gqa
knockout mice. In male Gqa knockout mice, serum testos-
terone levels increased from 1 6 0 ng/ml to 14 6 2 ng/ml
(n 5 7) in response to an sc injection of 2 mg of Buserelin. In
the male heterozygous mice, a similar treatment of Buserelin
increased serum testosterone levels from 1 6 0 ng/ml to 17 6
2 ng/ml (n 5 5). In female Gqa knockout mice there was no
significant change in serum estradiol levels in response to
2 mg of Buserelin; 5 6 2 pg/ml before Buserelin treatment,
and 4 6 2 pg/ml (n 5 3) 1 h after Buserelin treatment. The
same was true for female heterozygous mice; 4 6 1 pg/ml
before Buserelin treatment and 7 6 1 pg/ml (n 5 3) after
Buserelin treatment. There was no significant difference
between Gqa knockout mice and heterozygous mice, with
respect to Buserelin stimulated steroid (testosterone and
estradiol) release.
Discussion
In this study, we investigated the role of Gqa and G11a in
mouse gonadotrope function using knockout mice lacking
the Gqa or the G11a protein. The fact that these knockout mice
breed relatively normally immediately suggested that either
protein is not essential in the regulation of the gonadotrope;
potentially Gqa and G11a can substitute for each other. To
FIG. 5. A and B show the LH released, after 1 h, in response to the
indicated doses of Buserelin in G11a knockout male and female mice,
respectively. Samples were collected, and LH released was assayed by
RIA as mentioned in Materials and Methods. The data represent the
mean 6 SEM. Data points with asterisks are significantly different
(P , 0.05) from the corresponding data points for the control strain.
FIG. 6. A and B show the LH released, after 1 h, in response to the
indicated doses of Buserelin in Gqa knockout male and female mice,
respectively. Samples were collected, and LH released was assayed by
RIA as mentioned in Materials and Methods. The data represent the
mean 6 SEM. Data points with asterisks are significantly different
(P , 0.05) from the corresponding data points for the heterozygous
mice.
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examine the role of these two proteins in GnRH-stimulated
LH release, we examined the dynamics of GnRH-stimulated
LH release in mice. We used two different protocols to ad-
dress this question. First, we gave each mouse (control and
knockout) a single dose of Buserelin and subsequently mea-
sured the serum LH levels at the given times. This protocol
would show any differences in the release of LH between the
knockout mice and control mice in response to acute GnRH
analog treatment. Alternatively, we administered Buserelin
every 12 h for 108 h, and 1 h after each administration,
measured the serum LH levels. The second protocol would
address any differences in the LH release between the control
mice and knockout mice in response to chronic GnRH analog
treatment, and allow assessment of the development of de-
sensitization. To determine the sensitivity of the gonado-
trope, we performed an in vivo dose-response of Buserelin-
stimulated LH release in the knockout and control mice.
Furthermore, to determine whether any differences in Buse-
relin-stimulated LH release between knockout mice and con-
trol mice are due to different levels of gonadal steroids,
producing varying levels of negative feedback, we assayed
the serum testosterone and estradiol levels in male and fe-
male mice, respectively.
In the short time course study, in both sexes, we did not
observe any significant differences between the control strain
and the G11a knockout mice. In the long time course study,
the male G11a knockout mice had a rapid increase in serum
LH levels after Buserelin treatment compared with the con-
trol strain. Furthermore, in the male G11a knockout mice, the
serum LH levels were elevated above those of the control
mice up to 61 h after the start of treatment, indicating that the
knockout mice did not become refractory to the GnRH an-
alog as rapidly as did the control strain. Another possible
interpretation would be that LH is elevated to such an extent,
that it takes a longer time to return to control plasma levels.
The short time course studies, in both sexes of the Gqa
knockout mice, showed no significant differences in LH re-
lease in response to a GnRH analog when compared with the
control heterozygous strain. In the long time course studies,
both sexes showed a significant difference in the LH release
compared with heterozygous mice. The Gqa knockout male
mice released less LH than the heterozygous mice, and after
the initial LH flare, the LH levels in the heterozygous mice
FIG. 7. A and B show the testosterone and estradiol levels in the
serum, respectively, of male and female mice, before and 1 h after an
sc injection of 2 mg of Buserelin in G11a knockout mice. Samples were
collected and serum testosterone and estradiol levels were assayed as
mentioned in Materials and Methods. The data represent the mean 6
SEM. Data points with asterisks are significantly different (P , 0.05)
from the corresponding data point for the control strain.
FIG. 8. A and B show the serum testosterone and estradiol levels,
respectively, of male and female mice, before and 1 h after an sc
injection of 2 mg of Buserelin in Gqa knockout mice. Samples were
collected and serum testosterone and estradiol levels were assayed as
mentioned in the Materials and Methods. The data represent the
mean 6 SEM.
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never reached the basal levels achieved by the knockout
mice. Paradoxically, in the female Gqa knockout mice, Buse-
relin stimulated a higher level of LH release compared with
the control heterozygous strain.
Only G11a knockout mice and not Gqa knockout mice were
less sensitive to low doses of Buserelin with respect to LH
release. Stimulation of knockout mice with 5 ng of Buserelin
resulted in substantially less LH release than in the control
mice in G11a knockout mice. This may indicate different roles
for G11a and Gqa in the gonadotrope.
To determine whether the differential responses to Buse-
relin, with respect to LH release, was due to different levels
of gonadal steroids being released resulting in differing lev-
els of negative feedback on the gonadotrope, we examined
the serum testosterone and estradiol levels in male and fe-
male mice, respectively. Buserelin-stimulated serum testos-
terone levels in male G11a knockout mice was significantly
higher than in control mice, although Buserelin stimulated
estradiol levels in female G11a knockout mice were lower
than in control mice. In male and female Gqa knockout mice,
there were no significant differences in Buserelin-stimulated
gonadal steroid levels compared with control heterozygous
strain.
The fact that there was a difference in Buserelin-stimulated
LH release between the short and long time course studies
suggests that there is a differential response to Buserelin
under different treatment protocols. It is possible that mice
in the short time course protocol may be stressed, resulting
in a retarded response to Buserelin.
In the gonadotrope, LH release is under the negative feed-
back control of estrogen and testosterone. Therefore, if go-
nadal steroid production was affected in the knockout mice,
this could produce different intensities of negative feedback
on the gonadotrope resulting in differential levels of LH
release in response to Buserelin. The steroid data suggest that
negative feedback cannot account for the high LH release in
male G11a knockout mice in the long time course study,
because in the G11a knockout mice, the testosterone levels are
higher than in control mice. In Gqa knockout male mice,
Buserelin-stimulated LH release is lower than in the control
mice in the long time course study, although there is no
significant difference in testosterone production compared
with the control strain, at 1 h or 13 h after the start of Buserelin
treatment. Therefore the differences in the Buserelin-stimu-
lated LH release in the knockout mice compared with the
control mice cannot be clearly explained with the differing
steroid levels. In the female G11a knockout mice we could not
detect an increase in the serum estradiol production after
Buserelin stimulation, although in the control wild-type mice
we measured a Buserelin-stimulated increase in serum es-
tradiol production. The absence of a Buserelin-stimulated
estradiol increase in female G11a knockout mice may be a
physiological manifestation of G11a absence, or may be a
technical artifact due to serum estradiol levels too low to
detect with our assay. In the female Gqa knockout mice, we
could not detect an increase in serum estradiol in response
to Buserelin. However, there were no significant differences
in the serum estradiol production between the knockout
mice and the control heterozygous mice. This may indicate
that Gqa does not play a role in Buserelin-stimulated estra-
diol production in these mice, although, as mentioned ear-
lier, this observation may be due to low serum estradiol
levels compared with the sensitivity of our assay.
The fact that in the long time course study, Buserelin-
stimulated LH release is higher in male G11a knockout mice
than in control (Fig. 2), whereas in male Gqa knockout mice,
Buserelin-stimulated LH release is lower than in the control
strain (Fig. 4), suggests that these proteins may play a dif-
ferent role in LH synthesis. A disruption in LH synthesis,
manifested as a difference in Buserelin-stimulated LH release
in the long time course experiments cannot be discounted in
these knockout mice.
The differences between male control mice and male G11a
knockout mice, with regard to Buserelin-stimulated LH re-
lease and testosterone production, may be due to the fact that
the control mice and the knockout mice were from two dif-
ferent breeding groups. However, this is unlikely, as the
strain of the two groups of mice were the same (129/
SvEvTacfBR). Similarly, the differences between the het-
erozygous mice and Gqa knockout mice, with respect to LH
release, are not likely due to differences in strain, age or
pubertal status, as we tried to use mice from the same litter
group.
The reason for a sex based difference in Buserelin-stimu-
lated LH release in Gqa and G11a knockout mice is unclear.
One possibility is that there may be differences in the sexual
maturation time between males and females, although how
this may affect Buserelin-stimulated LH release is not
known. It would be interesting to see whether there are other
sex based differences in these G protein knockout mice.
The changes in serum LH levels observed between the
knockout mice and the control mice is not due to differences
in degradation, because serum LH clearance is dependent on
sialation of the protein. Changes in sialation is observed in
different aged animals, and we used mice that were of similar
age (26).
This study shows that there are differences in the dynam-
ics of LH release in response to chronic GnRH analog treat-
ment. The lack of complete abolition of processes, such as
stimulated LH release and steroid production, suggest that
these G proteins are either not required or are able to func-
tionally compensate for each other. Experiments similar to
this study will have to be performed with conditional double
knockouts of G11a and Gqa to determine whether these pro-
teins are required for GnRH activity in the pituitary.
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